XSHE
002422
Market cap8.33bUSD
Jun 16, Last price
35.98CNY
1D
-2.18%
1Q
15.17%
Jan 2017
123.20%
IPO
0.78%
Name
Sichuan Kelun Pharmaceutical Co Ltd
Chart & Performance
Profile
Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, manufactures, distributes, and sells pharmaceutical products in China. It offers IV solutions; injectable powder and small volume parenteral; oral preparation; intermediates and APIs; and peritoneal dialysis solutions. The company was founded in 1996 and is based in Chengdu, the People's Republic of China. Sichuan Kelun Pharmaceutical Co., Ltd. is a subsidiary of Sichuan Kelun Industry Group CO., LTD.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 21,453,929 13.44% | 18,912,653 9.46% | |||||||
Cost of revenue | 17,070,315 | 15,751,923 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 4,383,614 | 3,160,730 | |||||||
NOPBT Margin | 20.43% | 16.71% | |||||||
Operating Taxes | 933,787 | 364,002 | |||||||
Tax Rate | 21.30% | 11.52% | |||||||
NOPAT | 3,449,827 | 2,796,728 | |||||||
Net income | 2,456,112 44.03% | 1,705,324 96.44% | |||||||
Dividends | (1,126,708) | (597,780) | |||||||
Dividend yield | 2.51% | 1.51% | |||||||
Proceeds from repurchase of equity | 13,882 | (106,457) | |||||||
BB yield | -0.03% | 0.27% | |||||||
Debt | |||||||||
Debt current | 4,205,128 | 5,319,441 | |||||||
Long-term debt | 3,139,040 | 4,762,469 | |||||||
Deferred revenue | 288,206 | 208,884 | |||||||
Other long-term liabilities | 78 | ||||||||
Net debt | (3,593,932) | 1,549,149 | |||||||
Cash flow | |||||||||
Cash from operating activities | 5,337,069 | 3,127,457 | |||||||
CAPEX | (1,769,185) | (896,022) | |||||||
Cash from investing activities | (3,370,325) | (856,590) | |||||||
Cash from financing activities | (2,058,766) | (407,261) | |||||||
FCF | 1,671,799 | 2,283,737 | |||||||
Balance | |||||||||
Cash | 6,945,956 | 5,173,412 | |||||||
Long term investments | 3,992,143 | 3,359,350 | |||||||
Excess cash | 9,865,403 | 7,587,129 | |||||||
Stockholders' equity | 15,395,221 | 13,355,120 | |||||||
Invested Capital | 20,537,416 | 19,288,254 | |||||||
ROIC | 17.32% | 14.70% | |||||||
ROCE | 14.29% | 11.65% | |||||||
EV | |||||||||
Common stock shares outstanding | 1,544,725 | 1,485,828 | |||||||
Price | 29.05 9.17% | 26.61 40.57% | |||||||
Market cap | 44,874,248 13.50% | 39,537,892 47.76% | |||||||
EV | 44,623,532 | 42,223,771 | |||||||
EBITDA | 5,642,373 | 4,333,232 | |||||||
EV/EBITDA | 7.91 | 9.74 | |||||||
Interest | 370,709 | 473,710 | |||||||
Interest/NOPBT | 8.46% | 14.99% |